BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...

Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

Glucose homeostasis is maintained primarily by the action of the two pancreatic hormones, insulin and glucagon, in conjunction with a host of other modulators. (Röder et al., 2016). Beta- and ...

Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to ...

Increasing activity of the transcription factor cAMP response element-binding protein (CREB) in young adult rodents facilitates cognition, and increases intrinsic excitability. However, it has yet to ...

Glucagon-like peptide-1 released from intestinal L cells acts on the pancreas and brain to reduce food intake. Amylin is secreted from the pancreas and can reduce food intake. Drugs Approved by the ...